Karo Pharma AB - ESG Rating & Company Profile powered by AI
This report of Karo Pharma AB was prepared by All Street Sevva using leading AI. The page is a zero-cost Sustainability assessment for Karo Pharma AB. Detailed ESG assessment of Karo Pharma AB are accessed by signing up for free.
Karo Pharma AB in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.5; made up of an environmental score of 0.0, social score of 0.0 and governance score of 1.6.
0.5
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1898 | Zota Health Care Ltd | 0.7 | Low |
1898 | cbdMD Inc | 0.7 | Low |
1924 | Karo Pharma AB | 0.5 | Low |
1924 | Beximco Pharmaceuticals Ltd | 0.5 | Low |
1924 | Acucela Inc | 0.5 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Karo Pharma AB have an accelerator or VC vehicle to help deliver innovation?
Does Karo Pharma AB disclose current and historical energy intensity?
Does Karo Pharma AB report the average age of the workforce?
Does Karo Pharma AB reference operational or capital allocation in relation to climate change?
Does Karo Pharma AB disclose its ethnicity pay gap?
Does Karo Pharma AB disclose cybersecurity risks?
Does Karo Pharma AB offer flexible work?
Does Karo Pharma AB have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Karo Pharma AB disclose the number of employees in R&D functions?
Does Karo Pharma AB conduct supply chain audits?
Does Karo Pharma AB disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Karo Pharma AB conduct 360 degree staff reviews?
Does Karo Pharma AB disclose the individual responsible for D&I?
Does Karo Pharma AB disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Karo Pharma AB disclose current and / or historical scope 2 emissions?
Does Karo Pharma AB disclose water use targets?
Does Karo Pharma AB have careers partnerships with academic institutions?
Did Karo Pharma AB have a product recall in the last two years?
Does Karo Pharma AB disclose incidents of discrimination?
Does Karo Pharma AB allow for Work Councils/Collective Agreements to be formed?
Has Karo Pharma AB issued a profit warning in the past 24 months?
Does Karo Pharma AB disclose parental leave metrics?
Does Karo Pharma AB disclose climate scenario or pathway analysis?
Does Karo Pharma AB disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Karo Pharma AB disclose the pay ratio of women to men?
Does Karo Pharma AB support suppliers with sustainability related research and development?
Does Karo Pharma AB disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Karo Pharma AB reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Karo Pharma AB involved in embryonic stem cell research?
Does Karo Pharma AB disclose GHG and Air Emissions intensity?
Does Karo Pharma AB disclose its waste policy?
Does Karo Pharma AB report according to TCFD requirements?
Does Karo Pharma AB disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Karo Pharma AB disclose energy use targets?
Does Karo Pharma AB disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Karo Pharma AB have a policy relating to cyber security?
Have a different question?
Potential Risks for Karo Pharma AB
These potential risks are based on the size, segment and geographies of the company.
Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally. It offers skin health products under the Remescar, Locobase, Decubal, and indy beauty brand names; intimate health products under the Pevaryl, Multi Gyn, Asan, and Selexid brand names; and foot health products under the Pevaryl, CCS, Nailner, and wortie brands. The company also provides pain, cough, and cold products under the Paracet, Ibux, Mollipect, and Viruseptin brand names; prescription drugs under the Burinex, Centyl, Kaleorid, and Lithionit brands; and wellness products under the nutravita, Alpha Foods, Flux, Allévo, Dosett, Dax, and Lactocare brands. It sells its products in approximately 90 countries with Europe and the Nordic region markets through direct sales organizations and a network of distributors, as well as online. The company was formerly known as Karo Bio AB (publ) and changed its name to Karo Pharma AB (publ) in March 2016. Karo Pharma AB (publ) was incorporated in 1987 and is headquartered in Stockholm, Sweden.